This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short

RBC Capital analyst Michael Yee offers seven reasons why Biomarin Pharmaceuticals will secure U.S. approval for drisapersen to treat Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease.

Intra-Cellular Keeps Investors in Dark About Schizophrenia Drug Study

Investors asking Intra-Cellular for a copy of the scientific poster needed to conduct proper due diligence on ITI-007 are told they can't have it.

MannKind Afrezza Sales Underwhelming Again, Sanofi Reports

The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.

MannKind Relies on 'Death Spiral' Financing to Help Settle Looming Debt

MannKind isn't at risk of shutting down imminently because of the death-spiral convert, but the company was forced into a weakened negotiating position because Afrezza is selling poorly.

Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)

Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.

Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches

It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news.

Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings

Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up

After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?

Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head

After 34 years in existence, Xoma still can't develop a drug successfully on its own.

Eli Lilly's Solanezumab Is the Alzheimer's Drug Equivalent of the Internet Dress

Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.

Page 2 of 340
Top Rated Stocks Top Rated Funds Top Rated ETFs